BIOCENTURY reported that FDA is shifting away from a punitive structure under the “America First” PDUFA framework and toward a reward-based model. The change would reduce first-in-human-related overseas penalties by cutting fees by about $2 million for domestic trials, instead of imposing a $10 million penalty, according to the report. The update reflects a regulatory stance realignment that could affect how sponsors structure early clinical programs and where first patient dosing occurs. It also comes amid broader policy debates on incentives for U.S.-based innovation and development. For biotech leaders, the immediate implication is a changed economics of trial siting during the first-in-human stage, which can influence corporate planning for timelines and budgeting for IND-enabling packages and early readouts.